Depression is a term that has been used to describe a variety of ailments, ranging from minor to incapacitating. Clinically significant depression, termed as major depression, is a serious condition characterized not only by depressed mood but also by a cluster of somatic, cognitive, and motivational symptoms. Significant research efforts are aimed to understand the neurobiological as well as psychiatric disorders, and the evaluation of treatment of these disorders is still based solely on the assessment of symptoms. In order to identify the biological markers for depression, we have focused on gathering information on different factors responsible for depression including stress, genetic variations, neurotransmitters, and cytokines and chemokines previously suggested to be involved in the pathophysiology of depression. The present review illustrates the potential of biomarker profiling for psychiatric disorders, when conducted in large collections. The review highlighted the biomarker signatures for depression, warranting further investigation.
Introduction
Depression is a term that has been used to describe a variety of ailments, ranging from minor to incapacitating.
Clinically significant depression, termed as major depression, is a serious condition characterized not only by depressed mood but also by a cluster of somatic, cognitive, and motivational symptoms. Major depression can be differentiated from a normal and transient sad mood by several factors, such as intensity, as major depression causes impairment in social or occupational functioning and persists across time and situations.
Relationship to antecedent events, as major depression either occurs without any identifiable antecedent event or, is clearly in excess of what would be considered an expected reaction. Emotion being different from that experienced in a normal sad mood. Associated features are the mood co-occurs with a group of other cognitive and somatic symptoms. Individuals who are suffering from major depression often report feeling overwhelmed, helpless, despairing, suffocated, or numb.
Factors responsible for depression

Stress
Stress is a term that means different things to different people, but generally has a negative connotation. [1] Stress is a familiar aspect of modern life and is a stimulant for some individuals, but a problem for many others.
Stress has been defined as a constellation of events, which begins with a stimulus (stressor) that precipitates a reaction in the brain (stress perception), which subsequently activates physiologic systems in the body (stress response). [2, 3] The physiologic stress response results in the release of neurotransmitters and hormones that serve as the brain's messengers to the rest of the body. The consequences of this physiologic response are generally adaptive in the short run, but can be damaging when stress is chronic and long lasting. [4, 5] Chronic stress is long-term, negative stress that has become detrimental to the individual, while acute stress is short-term, positive stress that is relatively harmless to the individual and often gives an extra burst of energy that is needed during the stressful period. An important marker of the deleterious effects of chronic stress is a breakdown in the regulation of the circadian corticosterone rhythm in rodents and cortisol rhythm in humans. [6] Chronic stress seems to be linked to the etiology of many diseases.
A number of studies have shown that stress can be immunosuppressive and hence that it can be detrimental to health. Moreover, glucocorticoid stress hormones are regarded widely as immunosuppressive [7] and are used clinically as anti-inflammatory agents. [8] 
Genetic variability
Genetic factors have been implicated in the etiology of depression and many studies have determined that changes in protein structure correlate with a predisposition to specific conditions. More than 10 million single nucleotide polymorphisms (SNPs) have been identified in humans; however, the importance of most SNPs for health and disease is not understood. Most SNPs are indeed unimportant and because of often inadequately powered studies, many observations on SNP effects cannot be repeated by other researchers.
SNPs are at best shown to influence protein function or level, rarely to influence risk of disease, and almost never to influence total mortality, the ultimate endpoint. However, specific genes or relevant DNA sequence variations involved in the pathogenesis of depression
have not yet been identified.
Major depressive disorder (MDD) is common and moderately heritable. Recurrence and early age at onset characterize cases with the greatest familial risk. MDD and the neuroticism personality trait have overlapping genetic susceptibilities. Most genetic studies of MDD have considered a small set of functional polymorphisms relevant to monoaminergic neurotransmission. Metaanalyses suggest small positive associations between the polymorphism in the serotonin transporter promoter region (5-HTTLPR) and bipolar disorder, suicidal behavior, and depression-related personality traits but not yet to MDD itself. This polymorphism might also influence traits related to stress vulnerability. Newer hypotheses of depression neurobiology suggest closer study of genes related to neurotoxic and neuroprotective (neurotrophic) processes and to overactivation of the hypothalamic-pituitary axis, with mixed evidence regarding association of MDD with polymorphisms in one such gene brain-derived neurotrophic factor (BDNF). [9] MDD has been a growing public health concern due to its recurrent, deliberate, and lethal nature. According to projections, MDD will become the second leading cause of disability worldwide by the year 2020. [10] By the year 2030, it is estimated to be the highest cause of disability in high-income countries and still the second cause of burden of disease globally. Having been recognized as a multifactorial disease, the total contribution of genetic factors in the origin of disease, the heritability, is estimated at nearly 40%. [11] Notably, the mode of inheritance is complex and ambiguous. Thus, relevant DNA sequence variations in poten tial candidate genes contributing to the susceptibility to MDD remain to be explored. Studies on norepinephrine and serotonin pathways have highlighted the molecular role of these neurotransmitter systems in the pathophysiology of MDD. Nevertheless, the role of dopamine (DA) neurotransmission in MDD has gained increasing attention since the earliest report in the mid-1970s. [12] Clinically, changes in both serotonergic and dopaminergic activity have been observed in patients with MDD receiving long-term treat ment with antidepressants. [13] Also, therapy using dopaminergic agents in treatment-resistant patients with MDD has been demonstrated to enhance the action of antidepressant medications. [14] Furthermore, antidepressants with direct dopaminergic effects have been well documented. [15] Research findings have consistently emphasized the molecular connection between genes associated with dopaminergic activity and the pathophysiology of MDD. [16, 17] The dopaminergic system, which consists of DA-producing cells, DA receptors and DA transporters (DAT1, also referred to as SLC6A3), may play a crucial role in MDD. In particular, DAT1 proteins play a significant role in the reuptake of DA into presynaptic neu rons and limit the duration of synaptic activity, thus being the key regulators of DA level in the brain. In humans, the DAT1 gene, located at chromosome 5q35.1, contains 15 exons, [18, 19] and its expression occurs in all DA neurons, including those originating in the substantia nigra and ventral tegmentum. [20] Although several lines of evidence suggest an association between (G x E) interaction in the etiology of MDD. [21] This particular SNP has also been found to play a genetic role in certain neuropsychiatric and neurological illnesses such as attention deficit hyperactivity disorder, bipolar disorder, [22] and migraine with aura. [23] The norepinephrine transporter (NET), a Na/Cldependent substrate specific transporter, terminates noradrenergic signaling by rapid reuptake of neuronally released norepinephrine into presynaptic terminals. NET exerts a fine regulated control over norepinephrinemediated physiological effects such as depression.
As the 50 flanking promoter region of the NET gene,
NET T-182C, contains several cis elements that play a critical role in transcription regulation, [24, 25] changes in this promoter DNA structure may lead to an altered transcriptional activity responsible for a predisposition to MDD. [26] Although a silent G1287A polymorphism, located at exon 9 of the NET gene, is not an important factor in susceptibility to depression in a Japanese population, [27] but it cannot be denied that it may be an important candidate. BDNF is a nerve growth factor that has antidepressant-like effects in animals and may be implicated in the etiology of mood-related phenotypes. than in women. [28] In order to further clarify the impact of BDNF gene variation on major depression as well as antidepressant treatment response, association of three BDNF polymorphisms [rs7103411, Val66Met (rs6265) and rs7124442] with major depression and antidepressant treatment response was investigated. [29] All SNPs had main effects on antidepressant treatment response. Results do not support an association between genetic variation in BDNF and antidepressant treatment response or remission. Preliminary studies suggest a potential minor role of genetic variation in BDNF and antidepressant treatment outcome in the context of melancholic depression. [30] Identification of novel genetic Depression Rating Scale. [31] Alterations in BDNF-signaling pathways may play an important role in the pathophysiology of MDD. Five SNPs in three BDNF signal-transduction pathway genes (BDNF, GSK3B, and AKT1) were used in association
analyses. An allelic association between the GSK3B SNP rs6782799 and MDD was found in our samples. Further gene-gene interaction analyses showed a significant effect of a two-locus BDNF/GSK3B interaction with MDD (GSK3B rs6782799 and BDNF rs7124442) and also for a three-locus interaction (GSK3B rs6782799, BDNF rs6265, and BDNF rs7124442). These findings support the assertion that the GSK3B gene is an important susceptibility factor for MDD in a Han Chinese population. [32] Mounting evidence shows that brain-derived neurotrophic factor (BDNF) plays a crucial role in synaptic plasticity. Normally, BDNF sustains the viability of brain neurons. Under stress, however, BDNF gene is repressed, leading to atrophy and possible apoptosis Tamatam: Biomarkers of depression of vulnerable neurons in the hippocampus when their neurotrophic factor BDNF is absent. These events in turn lead to depression and to the consequences of repeated depressive episodes, namely, more and more episodes and less and less responsiveness to treatment. Due to its potential involvement in psychiatric diseases such as depression, BDNF became a major target in research.
A functional polymorphism of the BNDF Val66Met influences and reduces trafficking and secretion of BDNF protein in the brain and is thought to be associated with low BNDF levels in MDD. [33] [34] [35] [36] 
Neurotransmitters
The monoamine hypothesis proposes that depression is due to a deficiency in monoaminergic neurotransmission. [37, 38] and it can partly account for anxiety-related personality traits. Episode. SNP rs7997012 was significantly associated with remission after 5 weeks providing first replicative support for the initial finding, with however, an inverse allelic association as compared to the STARD sample. [39] Another common polymorphism is a variable number tandem repeat (VNTR) in intron 2 (STin2), which has three alleles consisting of either 9 (STin2.9), 10 (STin2.10), or 12 (STin2.12) repeats, were shown to be in linkage disequilibrium, with the positive association between the STin2 allele 10 and the 5-HTTLPR L allele. [40] Variation at the VNTR can also influence expression of the transporter with the polymorphic VNTR regions acting as transcriptional regulators [41] although it is likely to have no significant effect on function.
Tryptophan hydroxylase (TPH) is the enzyme involved in the biosynthesis of serotonin. It catalyzes the oxygenation of tryptophan to 5-hydroxytryptophan, which is decarboxylated to serotonin. [42] It is thus the ratelimiting enzyme in the biosynthesis of serotonin. Changes in the metabolism of the essential amino acid tryptophan play an important role in the brain-endocrine-immune system interaction that is hypothesized to be involved in the pathophysiology of MDD. There are two main pathways of tryptophan metabolism: one is the serotonin pathway and the other is the kynurenine (KYN) pathway. [43] Dysfunction of the serotonergic system has been hypothesized to play an important role in depression. The higher serotonergic activity during stress leads to a higher breakdown of serotonin. Sustained stress will lead to diminution of serotonin (synthesis/ degradation). Thus, chronic stress may lead to functional shortage of the supply of serotonin. Two genes have been discovered which encode for the TPH isoforms Tamatam: Biomarkers of depression (TPH1 and TPH2). Most of the molecular genetic studies on the TPH genes so far have examined the two polymorphisms of the TPH1, A218C and A779C, which have been found to be in complete or strong linkage disequilibrium in previous studies. [44] A polymorphism in intron 7 of TPH1, A218C, has been extensively examined in association studies, and the A allele is associated with anxiety symptoms in depression. [45] There is no association between the TPH2 polymorphisms and s t r e s s -i n d u c e d d e p r e s s i o n . [46, 47] the Met/Met genotype. [48] One of the European study reported an association between the Val/Val genotype and early onset MDD, [49] but conflicting results have been found in other studies with fewer participants. [50] As serotonin exerts its effect on specific receptors on the postsynaptic membranes, the serotonin receptor Including subtypes, there are a total of at least 14 different receptors based on their pharmacological responses to specific ligands, sequence similarities at the gene and amino acid levels, gene organization, and second messenger coupling pathways. [51] Several subtypes, including the 5-HTR1A, 5-HTR1B, 5-HTR2A, 5-HTR3, and 5-HTR4, act to facilitate neurotransmitter DA release, while the 5-HTR2C receptor mediates an inhibitory effect of serotonin on DA release. Most 5-HTR subtypes only modulate DA release when serotonin and/or DA neurons are stimulated, but the 5-HTR2C, characterized by high levels of constitutive activity, inhibits tonic as well as evoked DA release. [52] The 5-HTR1A is an important member of the large family of serotonin receptors. [53] The 5-HTR1A is located both at a postsynaptic and at a presynaptic level, in the first case, they mediate the action of serotonin on cortical and limbic neurons and in the second case, they act as serotonergic autoreceptors on serotonergic neurons in the raphe nuclei and prevent the release of serotonin by negative feedback. [54] In depressed individuals, the number of serotonin receptors, including the 5-HTR1A autoreceptors, is increased. [55] A common functional polymorphism C-1019G in the promoter region of the human 5-HT1A receptor gene has been reported, which may be useful in identifying psychopathology associated with altered function of the human 5-HT1A receptor. [56] DOPA decarboxylase is an enzyme implicated in two metabolic pathways, synthesizing two important neurotransmitters, DA and serotonin. [57] Following the hydroxylation of tyrosine to form 3,4-dihydroxy-Lphenylalanine (L-DOPA), catalyzed by tyrosine hydroxylase (TH), DDC decarboxylates L-DOPA to form DA. The TH is the initial and rate-limiting enzyme in the biosynthesis of catecholamine neurotransmitters and has been a candidate for possible involvement in the development of psychiatric illness. [58] Among polymorphisms in the TH gene identified so far, a pentaallelic polymorphism consisting of several numbers of tetranucleotide repeats [or microsatellite polymorphism (TCAT)n] in intron 1 and three SNPs, namely Val81Met, Leu205Pro, and Val468Met, may alter the functional activity of TH protein. A tetranucleotide repeat in intron 1 has been reported to play a role in psychiatric illnesses. [59] [60] [61] DA is the most abundant catecholaminergic neurotransmitter in the brain and is involved in the regulation of emotions, motivation, reward, and reinforcement behavior through the mesocorticolimbic pathway. [62] Preclinical and clinical studies incriminate the dopaminergic system in affective disorders. While hyperfunction of the dopaminergic system may lead to manic behavior, its hypofunction may lead to depressive symptoms. [63, 64] includes introns within their protein-coding regions. [65] On the basis of sequence similarity, the G subunits have been divided into four families (Gi, Gs, Gq, and G12). Heterotrimeric guanine nucleotide-binding proteins (G proteins) are signal transducers and are attached to the cell surface plasma membrane that connects receptors to effectors and thus to intracellular signaling pathways. [66] Receptors that couple to G proteins communicate signals from a large number of hormones, neurotransmitters, chemokines, and autocrine and paracrine factors. Many important hormones and neurotransmitters, including epinephrine, acetylcholine, DA, and serotonin, use the Gi and Go pathways to evoke physiological responses. In vitro and in vivo studies suggested that the -141C Ins/Del polymorphism may be directly responsible for the regulation of DRD2 expression and DRD2 function. [67] Ser311Cys in DRD2 has been reported to be associated with a reduced ability of activating the appropriate Gi-like protein. [68] Brain imaging studies of healthy volunteers have shown that individuals with an A1 allele (C allele of C32806T) of DRD2 have a reduced number of dopamine D2 receptors. [69, 70] The DRD3 Ser9Gly genotypes were reported to differ with regard to their DA-binding affinity. [71] The most widely studied polymorphism of DRD4 is a 48-bp variable number of tandem repeats (VNTRs) which encodes for the third intracytoplasmic loop and contains 2-11 repeats. [72] A 48-base pairs repeat in exon 3 of DRD4 was associated with the potency of inhibition of cAMP formation by DA. [73] The DRD4 48-base pairs repeat in the exon 3 was significantly associated with major depression while the DRD2 Ser311Cys and DRD3 S e r 9 G l y p o l y m o r p h i s m s w e r e n o t . [74] T h e s e polymorphisms may be hypothesized to influence MDD. These polymorphisms have been reported to increase the susceptibility to depression, although negative findings have also been reported.
GABA is the main inhibitory neurotransmitter in the mammalian central nervous system and regulates many physiological and psychological processes. Both animal and human studies associate variations in GABA in the mammalian forebrain with anxiety and depression. [75] The GABAA receptor is the site of action for anxiolytic drugs of the benzodiazepine and barbiturate classes. Also, GABA concentrations are increased with selective serotonin reuptake inhibitors (SSRIs), the other major drug class currently used to treat ANX as well as depressive disorders. Thus, GABA is strongly implicated in multiple anxiety-related processes. Although GABA acts through both GABAA and GABAB receptors to decrease neurotransmission. [76] In particular, several studies have documented altered benzodiazepine binding at cerebral GABAA receptors in panic disorder. [77, 78] Functional GABAA receptors are typically constructed of five subunits drawn from eight different classes (α, β, etc.). Each subunit is encoded by a distinct gene and differentially expressed in the brain, suggesting that mutation in any one gene could, in principle, contribute to the symptoms of anxietyrelated disorders. The GABAA α2 subunit, primarily expressed in the limbic system, likely mediates the anxiolytic effects of benzodiazepines. [79] The gene that encodes this protein, GABRA2, has been associated with alcohol dependence in several studies. [80, 81] ANX is known to have high co morbidity rates with alcoholism, and one study suggests that part of the association of this gene with alcohol dependence may be accounted for by anxious temperament. [82] Pharmacological studies have specifically implicated the GABAA α3 subunit in anxiety. [83] Genetic studies of GABRA3 gene also support its potential role in mood disorder phenotypes. Recent studies provided evidence that mice with global deletion of the GABRA3 gene had more depression-related behaviors. [84] The human GABRA3 gene is located in Xq28 region, an area that has been linked to the genetic transmission of bipolar affective disorder. [85] Genetic association has been reported between the GABRA3 and both bipolar [86] and unipolar [87] mood disorders, although earlier studies failed to detect these associations. [88, 89] GABRA6 is involved in several factors contributing to ANX pathology. Sen and colleagues (1991) [90] reported an association between a GABRA6 receptor coding polymorphism and neuroticism a personality trait related to both anxiety and depression. Variation in GABRA6 has also been associated with increased production of cortisol and increased blood pressure in response to psychological stress. [91] A broad role of GABRG2 in anxiety-related behavior was demonstrated, whereby γ2 heterozygous mice with resulting reduced GABAA receptor clustering showed increased fear of a novel environment. [92] Tamatam: Biomarkers of depression S100B is a neurotrophic factor that is involved in neuroplasticity. Neuroplasticity is disrupted in depression; however, treatment with antidepressants can restore neuroplasticity. S100B has previously been used as a biological marker for neuropathology and neuroplasticity.
The difference in the serum S100B levels between depressive patients and normal controls and between antidepressant responders and non-responders was compared. Serum S100B level is associated with the subsequent response to antidepressants. The high baseline serum S100B level that was observed in depressive patients may enhance neuroplasticity, which results in a favorable therapeutic response to antidepressants. [93] Nontraditional gene candidates such as PCLO and GRM7 are now emerging and beginning to change the landscape for future human and animal research on depression. [94] Immune biomarkers A role of inflammation in depression was first proposed by Smith (1991) . [95] Since then, several studies have reported a link between MDD, or depressive symptoms, and a variety of inflammatory and immune biomarkers. [96] [97] [98] Depression may cause inflammation through altered neuroendocrine function and central adiposity. [99] However, depression may also be a consequence of inflammation, since a pathogenic role of inflammatory cytokines in the etiology of depression has been described. [100] Although given less consideration, a third possibility is that depression is a marker of some other underlying dimension that is separately linked to depression and inflammation. Recently, it has been proposed that such underlying factor could be a specific genetic makeup. [101] MPO is an enzyme of the innate immune system, which exhibits a wide array of proatherogenic features. [102] MPO is secreted upon leukocyte activation, contributing to innate host defenses. However, it also increases oxidative stress, thereby contributing to tissue damage during inflammation and atherogenesis. MPO generates numerous reactive oxidants that cause lipid peroxidation, posttranslational modifications to target proteins, and decrease of nitricoxide bioavailability resulting into oxidation of low density lipoproteins LDL and apolipoprotein A1, protein carbamylation, and endothelial dysfunction. [103] Transgenic mice containing the human MPO gene show significantly larger atherosclerosis build up than the wild type. [104] In humans, individuals with total or subtotal MPO deficiency, a defect with a frequency of 1 in every 2000 to 4000 whites, are less likely to develop cardiovascular diseases and those harboring a promoter polymorphism associated with a 2-fold reduction in MPO expression appear cardioprotected. [103] Oxidative stress has also been linked to neuronal degeneration in the central nervous system. [105] MPO is both expressed and enzymatically active in the human brain and is associated with Alzheimer's disease. [106] Earlier studies have described abnormalities of oxidant-antioxidant systems in MDD suggestive of higher oxidative stress.
For example, elevated levels of antioxidant enzymes, particularly superoxide dismutase (SOD) and biomarkers of oxidation, such as malondialdehyde, were found in plasma, red blood cells, or other peripheral tissues of acutely depressed MDD patients compared with controls.
In some cases, [107] but not others, [108] these abnormalities were reduced with antidepressant treatment. SOD coenzyme concentrations are also higher in postmortem brain tissue (prefrontal cortex) of MDD patients than in control brains. [109] Overall, twins with MDD had 32% higher levels of MPO than those without MDD, an association that was not explained by other risk factors.
Other inflammatory biomarkers, except TNF-α, tended to be elevated in twins with MDD, in contrast to MPO however, these associations became weaker and mostly nonsignificant after adjusting for behavioral and coronary heart disease CHD risk factors. Depressive symptoms were not correlated with MPO, and adjustment for Beck Depression Inventory BDI score in the analysis did not alter the results for any of the biomarkers. It is possible that MPO is a more specific indicator of brain immune activation than other inflammatory biomarkers. MPO is a myeloid-specific enzyme produced by activated phagocytic cells, including brain microglia. In contrast, inflammatory cytokines are produced by a variety of cell types, while acute-phase proteins such as CRP and fibrinogen are mostly secondary products in response to cytokine signaling. [110] Thus, MPO is potentially a more specific marker of microglial immune activation prostaglandins. [111, 112] Associations between inflammatory markers and individual depressive symptoms such as fatigue, cognitive dysfunction, and impaired sleep have also been described. [113, 114] For example, both dysregulated sleep in depressed patients and sleep deprivation have been associated with increased interleukin (IL-6), as well as activation of nuclear factor kappa B (NF-κB), a primary transcription factor in the initiation of the inflammatory response. [114, 115] Although much of the interest in inflammation and depression has been focused on cytokines, which mediate the innate immune response, including IL-1β, tumor necrosis factor TNF-α and IL-6 which appears to be one of the most reliable peripheral biomarkers in major depression, [112, 116] findings of increased markers of T cell activation (e.g., soluble IL-2 receptor) in depressed patients raises the specter that both acquired (e.g., T and B cell) and innate (e.g., macrophage) immune responses may be involved. [116] Nevertheless, in contradistinction to the prominence of depression following administration of innate immune cytokines such as interferon IFN α to humans, [117, 118] administration of the T cell cytokine, IL-2, is not uncommonly associated with profound changes in mental status including psychosis, delirium and agitation. [119] In addition to correlative data linking inflammatory markers with depressive symptoms, several lines of evidence demonstrate that both acute and chronic administration of cytokines or cytokine inducers such as lipopolysaccharide (LPS) or vaccination can cause behavioral symptoms that overlap with those found in major depression. For example, normal volunteers injected with LPS exhibited acute increases in symptoms of depression and anxiety [120] and administration of a Salmonella typhi vaccine to healthy individuals produced depressed mood, fatigue, mental confusion, and psychomotor slowing. [121] In both cases, symptom severity correlated with increases in peripheral blood cytokine concentrations. These data in humans are consistent with a large literature in laboratory animals demonstrating that cytokines and cytokine inducers can lead to a host of behavioral changes overlapping with those found in depression, including anhedonia, decreased activity, cognitive dysfunction, and altered sleep. [122] Long-term exposure to cytokines has also been shown to lead to marked behavioral alterations in humans. For example, 20-50% of patients receiving chronic IFNα therapy for the treatment of infectious diseases or cancer develop clinically significant depression. Of note, depressive syndromes induced by IFN-α exhibit considerable overlap with idiopathic major depression and like idiopathic major depression, respond to conventional antidepressant medication. [117, 118] The inflammatory signaling molecule, NF-κB, has been found to be an essential mediator at the blood-brain interface that communicates peripheral inflammatory signals to the central nervous system CNS. Central blockade of NF-κB in rodents inhibits c-fos activation in multiple brain regions following peripheral administration of IL-1β while also inhibiting IL-1β-and LPS-induced behavioral changes. [123] Data indicate that peripheral cytokine signals can also access the brain in humans and activate relevant cell types that serve to amplify central inflammatory responses. For example, peripheral administration of IFN-α to patients with hepatitis C led to increased CSF IFN-α which correlated with increased CSF concentrations of IL-6 and the chemokine, monocyte chemoattractant protein (MCP-1). Monocyte chemoattractant protein-1, which is released by astrocytes and endothelial cells, has been found to prime microglia to produce IL-1 and TNFα in response to LPS in rodents, an effect that is reduced in MCP-1 KO animals. [124] Once cytokine signals reach the brain, they have the capacity to influence the synthesis, release, and reuptake of mood-relevant neurotransmitters including the monoamines. Literature on animals demonstrating that administration of cytokines or cytokine inducers can profoundly affect the metabolism of serotonin, Tamatam: Biomarkers of depression nor-epinephrine, and DA. [125, 126] Moreover, drugs (serotonin and nor-epinephrine reuptake inhibitors) and gene polymorphisms (serotonin transporter gene) that affect monoamine metabolism have been shown to influence the development of cytokine-induced depressive-like behavior in laboratory animals and humans. [127, 128] Regarding the mechanisms involved, much attention has been focused on the enzyme, indoleamine 2,3 dioxygenase (IDO). Through stimulation of multiple inflammatory signaling pathways, including signal transducer and activator of transcription 1a (STAT1a), interferon regulatory factor (IRF)-1, NF-κB, and p38 mitogen-activated protein kinase (MAPK), cytokines can activate IDO. [129] Indoleamine 2,3 dioxygenase, in turn, breaks down tryptophan (TRP), the primary amino acid precursor of serotonin, into KYN. The breakdown of TRP is believed to contribute to reduced serotonin availability. [122, 130] Supportive to induce depressive-like behavior in mice. [131] In addition, based on the differential expression of relevant metabolic enzymes, KYN is preferentially converted to kynurenic acid (KA) in astrocytes and quinolinic acid (QUIN) in microglia. [130] KA has been shown to inhibit the release of glutatmate, which, by extension, may inhibit the release of DA, whose release is regulated in part by glutamatergic activity. [132] Indeed, intrastriatal administration of KA has been shown to dramatically reduce extracellular DA in the rat striatum. [133] In contrast, QUIN promotes glutamate release through activation of N-methyl-D-aspartate (NMDA) receptors. QUIN also induces oxidative stress, which in combination with glutamate release may contribute to CNS excitotoxicity. [134] [135] [136] [137] Thus, the relative induction of KA versus QUIN may determine the effects of cytokines on the CNS and remains an important area for future investigation, including the therapeutic targeting of IDO and KYN enzymatic pathways. Cytokines also have been shown to influence the synthesis of DA. Intramuscular injection of recombinant, speciesspecific IFN-α to rats has been shown to decrease CNS concentrations of tetrahydrobiopterin (BH4) and DA in association with the stimulation of nitric oxide (NO).
Tetrahydrobiopterin is an important enzyme cofactor for tyrosine hydroxlylase, which converts tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA) and is the ratelimiting enzyme in DA synthesis. Tetrahydrobiopterin is also required for NO synthesis, and therefore increased NO generation is associated with increased BH4 utilization (thus decreasing the availability of BH4 to support tyrosine hydroxylase activity). Treatment with an inhibitor of NO synthase was found to reverse the inhibitory effects of IFN-α on brain concentrations of both BH4 and DA. [138] Activation of microglia is associated with increased NO production suggesting that cytokine influences on BH4 via NO may be a common mechanism by which cytokines reduce DA availability in relevant brain regions. Cytokines and their signaling pathways can also influence the reuptake of monoamines. Mitogenactivated protein kinase pathways, including p38 and extracellular signal-regulated kinases (ERK) 1/2, which mediate the effects of cytokines on cell proliferation/ differentiation and apoptosis, as well as gene expression of inflammatory mediators, increased the activity of membrane transporters for serotonin and DA, as well as norepinephrine. [139, 140] IL-1β and TNF-α have been shown to significantly increase serotonin reuptake in rat brain synaptosomes through activation of p38 MAPK. [140] Of note, activated p38 in peripheral blood mononuclear cells has been associated with decreased CSF concentrations of the serotonin metabolite, 5-hydroxyindoleactectic acid (5-HIAA), in juvenile Rhesus monkeys that were maternally abused as infants. [141] Extending these findings, recent data in humans administered IFN-α have revealed that decreased CSF 5-HIAA was correlated not only with depressed mood but also increased CSF IL-6, which is capable of activating both MAPK and IDO pathways. [111] Taken together with the influence of cytokines on monoamine synthesis, these data suggest that cytokines may exert a "double hit" on both monoamine synthesis and reuptake, thus contributing to reduced monoamine availability.
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Conclusions
It is concluded that the biomarkers such as genetic mutations, neurotransmitters, and cytokines can be used further for the identification of depressive conditions in the patients. At present, the mechanism for the development of depression is not well understood. Therefore, further research is required to understand the molecular basis at cellular level for its effective treatment.
